Fights over Tylenol, SSRIs highlight enduring lack of pregnant women in drug trials

Women have to wade through a chaotic data landscape, and many may choose to suffer through untreated illnesses.

October 2, 2025 Check out STAT+

Sponsored By

Have you listened to the new season of the "First Opinion Podcast" yet? This week, Torie Bosch sits down with science social media star Dr. Noc to chat about how he built a massive, and reliable, platform. And sign up for alerts when episodes drop each week.

Adobe STAT+ | Fights over Tylenol, SSRIs highlight the enduring lack of pregnant women in drug trials Shutting pregnant women out of clinical trials to protect them and their babies has had the opposite effect, experts say. By Lizzy Lawrence STAT+ | A long-trusted physician's reference finally catches the AI wave Doctors are increasingly turning to AI chatbots from UptoDate, OpenEvidence, and Pathway to answer clinical questions. By Katie Palmer STAT+ | UnitedHealth taps Duke scientist to lead AI efforts UnitedHealth Group has tapped a Duke artificial intelligence expert to be its chief AI scientist as it ramps up use of AI. By Casey Ross Mary Altaffer/AP Opinion: Yes, Amish people do have autism, but we still don't know how many do It is clear that some Amish do have autism. But direct comparisons between autism in the Amish and in the U.S. at large are difficult By Braxton D. Mitchell STAT+ | The biotech scorecard for the fourth quarter: 36 stock-moving events to watch Here's a look at top trial readouts and FDA drug approval decisions for Summit Therapeutics, BridgeBio, and other biotech companies. By Adam Feuerstein STAT+ | WHO says the antibacterial pipeline reveals a dual crisis: scarcity and lack of innovation Antimicrobial resistance is one of the most urgent global health threats, causing over one million deaths annually By Ed Silverman Adobe Opinion: Why promising women's health companies die so often Women's health startups can't build a sustainable business model when the entire system is designed to prevent adoption at scale. By Veronica Adamson A pharma C-suite shakeup and Trump's deal with Pfizer This episode, we discuss Emma Walmsley's tenure as GSK's CEO and break down President Trump's "most-favored nation" pricing deal with Pfizer. By Allison DeAngelis and Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser